Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2021

View Archived Issues

Synthesis and optimization of LRRK2 inhibitors using a CHK1-derived crystallographic surrogate

New MAP4K4 inhibitors identified for suppressing cardiac muscle cell death

New sporadic Alzheimer's disease animal model may improve drug testing

GABA-A alpha5 PAM RO-7015738 presented for neurological disorders

Genfleet Therapeutics discovers RIP-1 inhibitors

New IRAK-4/FLT-3 inhibitors identified at PharmaBlock Sciences

Amgen describes new PRMT5 inhibitors

New EGFR mutant inhibitors identified at Betta Pharmaceuticals

New DNA vaccine shows promise against Ebola virus infection

Microglial activation and tau spreading correlate with Braak stages in AD

NIH develops PET radioligands targeting CSF-1R for neuroinflammation

ProQR and Lilly to use Axiomer RNA editing platform to target liver and nervous system disorders

Update from large animal pilot dosing study of BB-301 for oculopharyngeal muscular dystrophy

mRNA-1273 vaccine induces antibodies against SARS-CoV-2 variants

Herantis advances project to combine Nanoform's technology with rhCDNF for Parkinson's disease

Reprogramming the tumor-immunosuppressive microenvironment to control metastasis

Researchers give rationale on the development of RAF-selective MEK inhibitors for cancer

Gut bacteria accumulate multiple therapeutic drugs

PAQ and Insilico Medicine collaborate to develop therapies through autophagy-dependent degradation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...